Abstract
Mitochondrial antiviral signaling protein (MAVS), an adaptor protein, is activated by RIG-I, which is critical for an effective innate immune response to infection by various RNA viruses. Viral infection causes the RIG-I-like receptor (RLR) to recognize pathogen-derived dsRNA and then becomes activated to promote prion-like aggregation and activation of MAVS. Subsequently, through the recruitment of TRAF proteins, MAVS activates two signaling pathways mediated by TBK1-IRF3 and IKK- NF-κb, respectively, and turns on type I interferon and proinflammatory cytokines. This study discovered that NEDD4 binding protein 3 (N4BP3) is a positive regulator of the RLR signaling pathway by targeting MAVS. Overexpression of N4BP3 promoted virus-induced activation of the interferon-β (IFN-β) promoter and interferon-stimulated response element (ISRE). Further experiments showed that knockdown or knockout N4BP3 impaired RIG-I-like receptor (RLR)-mediated innate immune response, induction of downstream antiviral genes, and cellular antiviral responses. We also detected that N4BP3 could accelerate the interaction between MAVS and TRAF2. Related experiments revealed that N4BP3 could facilitate the ubiquitination modification of MAVS. These findings suggest that N4BP3 is a critical component of the RIG-I-like receptor (RLR)-mediated innate immune response by targeting MAVS, which also provided insight into the mechanisms of innate antiviral responses.
Introduction
As the first barrier system of the body, innate immunity plays a vital role in removing foreign pathogens and guiding the body to produce effective adaptive immune responses. During the viral invasion, pathogen-associated molecular patterns (PAMPs) are initially recognized, which ultimately induces downstream effector genes, including type I interferons (IFNs) and proinflammatory cytokines (Akira et al., 2006). PAMP can be recognized by pattern recognition receptors (PRRs) to activate downstream signaling pathways. Typical pattern recognition receptors include endodermal location transmembrane Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs) (Janeway and Medzhitov, 2002; Takeuchi and Akira, 2010). TLRs recognize single-stranded or double-stranded RNA viruses in immune cells, while RLRs recognize viruses in non-immune cells (Kawai and Akira, 2011). The RLRs family consists of three members: retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated gene-5 (MDA5), and laboratory of genetics and physiology 2 (LGP2), which recognize double-stranded RNA viruses (Kang et al., 2002; Yoneyama et al., 2004; Saito et al., 2007). All RLRs have a C-terminal domain (CTD) and an intermediate RNA helicase domain that catalyzes ATP hydrolysis (Satoh et al., 2010). RIG-I and MDA5 also have CARDs at the N-terminal that interact directly with the MAVS to activate downstream signals (Venkataraman et al., 2007; Schlee et al., 2009; Schmidt et al., 2009). The expression of RLRs is ubiquitous. Although the expression of RLRs is always low in most types of cells, once it is infected by virus or stimulated by interferon, the expression of RLR will be rapidly induced.
Mitochondrial antiviral signaling proteins (MAVS), also known as Virus-induced signaling adapter (VISA), Cardif, and IPS-1, contain a C-terminal transmembrane domain inserted into the outer membrane of mitochondria and N-terminal CARD domain (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005). Activation of MAVS requires the formation of MAVS aggregates, mediated by the CARD in the cytosolic N terminus of MAVS that interacts with the tandem CARDs of RIG-I oligomers (Hou et al., 2011; Cai et al., 2014; Hui et al., 2014). Once MAVS is activated, these aggregates further recruit and activate other MAVS, thus forming large aggregates. When MAVS form prion protein aggregates, they can recruit E3 ubiquitin ligase and downstream effector proteins TNF receptor-associated factors 2 (TRAF 2), TRAF 3, and TRAF 6 to become an active “signaling body” (Liu et al., 2013). NEMO, a regulatory subunit of IKK and TBK1, is a ubiquitin sensor recruited into the MAVS/TRAFs complex through its ubiquitin-binding domain (Ea et al., 2006; Wu et al., 2006). NEMO then recruited IKK and TBK1 into the MAVS complex to activate IRF 3, IRF7, and NF-κB. The activation of IRF3 and IRF7 leads to autophosphorylation, which enters the nucleus to induce the type I IFN genes (Belgnaoui et al., 2011; Jacobs and Coyne, 2013; Liu et al., 2015; Shi et al., 2015; Vazquez et al., 2015). Similarly, activation of NF-κB phosphorylates P-65 into the nucleus and activates IFN genes expression.
As a member of the Fezzi family, the NEDD4 binding protein (N4BP3) has been reported to modulate axon and dendrite branches. It is expressed in the neural tissues of early Xenopus embryos, including the eyes, brain, and neural crest cells (Kiem et al., 2017). In addition, N4BP3 has certainly affected cell apoptosis and proliferation. N4BP3 is the interacting protein of NEDD4 ubiquitin ligase (Murillas et al., 2002). As an E3 ubiquitin ligase, NEDD4 plays a crucial role in various cellular processes through ubiquitination-mediated degradation of multiple substrates (Wang et al., 2020). However, the roles of N4BP3 in RLR-mediated signaling pathways have not been previously studied. In this study, we identified N4BP3 as an important regulator of RLR-mediated signaling pathways. Knockdown or knockout of N4BP3 can inhibit RLR-mediated activation of IRF3, induction of downstream antiviral genes, and cellular antiviral responses. Our findings reveal a previously unknown function of N4BP3 and provide insight into the mechanisms of innate antiviral responses.
Materials and Methods
Antibodies and Reagents
During this experiment, we used some essential antibodies: mouse monoclonal anti-Flag (Sigma-Aldrich, F3165), anti-HA antibodies (Sigma-Aldrich, H3663), anti-myc (Santa Cruz Biotechnology, sc-40), anti-IRF3 (Santa Cruz Biotechnology, sc-33641), rabbit monoclonal anti-N4BP3 (Proteintech, 16733-1-AP), anti-P65 and anti-P-P65 (Cell Signaling, #9936), Peroxidase-conjugated AffiniPure Goat anti-Rabbit IgG (H + L) (Jackson ImmunoResearch, 111-035-003), Goat anti-Mouse lgG(H + L)-HRP Conjugate (Bio-Rad, 172-1011). The dual-luciferase reporter assay system was obtained from Promega (Promega, E2610). ELISA kits were purchased from PBL Biomedical Laboratories (41415-1). Sendai virus (SeV) was kindly provided by Dr. Hong-Bing Shu (Wuhan University, Wuhan, China). Caspase inhibitor Z-VAD-FMK was purchased from Beyotime (C1202-0.02ml).
Cell Culture, Transfection, and Viral Infection
293T and MCF7 cells were retained in Dulbecco’s modified version Eagle’s medium (DMEM; Gibco), containing 10% fetal bovine serum (FBS; Gibco) and penicillin (100 U/ml)-streptomycin (0.1 mg/ml) (Grnview) at 37°C with 5% CO2. Transferred the plasmids needed for the experiment into the cells by the calcium phosphate transfection method. Added SeV to the cells 12 h after plasmids transfection. When the infection time was reached, the cells were collected and lysed.
Plasmids
Mammalian expression plasmids for human HA- or Flag-tagged RIGI, MAVS, TRAF2, TRAF3, Actb, Ubiquitin, and its mutants K48 and K63 Ubiquitin, myc-crmA, IFN-β promoter-luciferase reporter plasmid, and ISRE luciferase reporter construct were all provided by Prof. Hong-Bing Shu. The mammalian expression plasmid PRK5′-Flag or myc-tagged N4BP3 was constructed through strict molecular cloning technology. Similarly, we also got the N4BP3 plasmid of the PCMV vector. The following sequence is the primer sequence used to amplify human N4BP3 cDNA: AAAGTCGACCATGGCCACAGCCCCAGGCCCT (forward); AAAGCGGCCGCTCAGATCTTGGAGGACTCGAG (reverse).
To obtain the RNAi sequence, we can clone the corresponding double-stranded oligonucleotide target sequence into pSuper-Retro (Oligoengine, VEC-PRT-0002). The sequences were as follows:
#1: 5′-GCCAGAAGACAGCAGAGAT-3′;
#2: 5′-CCAGAAGACAGCAGAGATT-3′;
#3: 5′-GGCTTCCTATCCATGCAAA-3′;
#4: 5′-GCAAGAGCACCAAGAACAC-3′.
CRISPR-Cas9
CRISPR-Cas9 gene-editing technology is a technology for specific DNA modification of targeted genes, and it is also a cutting-edge method used in gene editing (Sanjana et al., 2014; Shalem et al., 2014). Through this technology, we need to insert the double-stranded oligonucleotide corresponding to the target sequence into the lentiCRISPR-V2 vector to obtain the KO plasmid, which was co-transfected with packaging plasmids into 293T cells. Two days after transfection, the viruses were harvested and used to infect 293T or MCF7 cells. The infected cells were selected with puromycin (1 μg/ml) for at least 5 days. The following sequences were targeted for human N4BP3 gDNA:
#1: 5′-GGCATTGCCATGGGCAGCGT-3′;
#2: 5′-CCGGAAGGGCTTGGGCCAGC-3′.
Co-immunoprecipitation and Immunoblotting and Native PAGE
Co-immunoprecipitation assays and western blot were performed as previously described (He et al., 2018). 293T cells were seeded in 60-mm dishes or 6-well plates and transfected with appropriate expression or Blank control plasmids. At 20 h post-transfection, cells were collected and lysed with lysis buffer containing [20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton, 1 mM EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM PMSF]. The Native PAGE was previously described (He et al., 2018).
Dual-Luciferase Reporter Assay
The specific methods were as described in the previous experiment (He et al., 2018). 293T cells were seeded in 24-well plates and transfected on the following day by a standard calcium phosphate precipitation method. To normalize transfection efficiency, pRL-TK (Renilla luciferase) reporter plasmid was added to each transfection mixture, together with the indicated plasmids or empty vector as a control, to ensure that each well contained the same amount of total DNA. Luciferase assays were performed using a dual-specific luciferase assay kit (Promega). All reporter assays were repeated at least three times.
ELISA
Culture supernatants of cells (∼2.5 × 105) seeded on 24-well plates or serum was collected and analyzed for cytokine levels with ELISA. ELISA kits for IFN-β were purchased from PBL Biomedical Laboratories. ELISA was performed according to the manufacturer’s instructions.
Quantitative Real-Time PCR
Quantitative Real-time PCR (Quantitative Real-time PCR) is a method that uses fluorescent chemicals to measure the total amount of product after each polymerase chain reaction (PCR) cycle in a DNA amplification reaction. Used the kit to extract total RNA from cells and performed reverse transcription to obtain cDNA. As mentioned before, quantitative real-time PCR analysis was performed (Ling et al., 2018). The primer sequences used for quantitative real-time PCR were as follows:
β-actin forward: GTCGTCGACAACGGCTCCGGCATG;
β-actin reverse: ATTGTAGAAGGTGTGGTGCCAGAT;
IFNB1 forward: CTAACTGCAACCTTTCGAAGC;
IFNB1 reverse: GGAAAGAGCTGTAGTGGAGAAG;
ISG56 forward: TCATCAGGTCAAGGATAGTC;
ISG56 reverse: CCACACTGTATTTGGTGTCTAGG;
CXCL10 forward: GGTGAGAAGAGATGTCTGAATCC;
CXCL10 reverse: GTCCATCCTTGGAAGCACTGCA.
Statistical Analysis
All histogram data analysis is performed using GraphPad Prism (version 8.0; GraphPad Software, Inc., La Jolla, CA, United States), and the values are the average and variance of three independent experiments. The One-way ANOVA and Two-Way ANVOA statistical methods were used. Asterisks are considered statistically significant, ∗P < 0.05; ∗∗P < 0.01; ns means no statistical significance.
Results
N4BP3 Is a Positive Regulator of the RIG-I-MAVS Antiviral Signal Pathway
The RLR signaling pathway plays an indispensable role in the process of virus infection. To further explore the RIG-I-MAVS antiviral signal mechanism, the yeast two-hybrid screening was performed by using the full length of MAVS as the bait, a few novel genes, including N4BP3, were identified as MAVS associated partners. To further confirm whether N4BP3 interacted with MAVS, the Flag-N4BP3 expression plasmid was co-transfected with empty vector, HA-labeled RIG-I, MAVS, and TBK1 plasmids, respectively, in 293T human kidney cells. The co-immunoprecipitation results indicated that N4BP3 interacted with RIG-1 and MAVS but not with TBK1 (Figure 1A and Supplementary Figure 1A).
FIGURE 1
By conducting a dual-luciferase reporter and ELISA assay in 293T cells, we found that N4BP3 could potentiate SeV-induced activation of IFN-β promoter and ISRE in a dose-dependent manner (Figures 1B,C). Consistently, N4BP3 overexpression dose-dependently increased MAVS-mediated activation of IFN-β promoter and ISRE (Figure 1D). The real-time fluorescence quantitative PCR experiments indicated overexpression of N4BP3 potentiated SeV-induced transcription of downstream genes, including IFNB1, ISG56, CXCL10 (Figure 1E). Overexpression of N4BP3 further increased SeV-induced and MAVS-mediated IRF3 dimerization and P-65 phosphorylation (Figures 1F,G). These results suggest that N4BP3 potentiates the RNA virus-triggered induction of downstream antiviral genes.
Knockdown of N4BP3 Inhibits RIG-I-MAVS Antiviral Signaling Pathway
To further determine its physiological role in the RIG-I-MAVS antiviral signaling mechanism, we used RNA interference techniques to reduce endogenous N4BP3 expression levels. We constructed four N4BP3-RNAi plasmids (#1, #2, #3, and #4), which could knock down the expression of N4BP3 to various degrees. Transient transfection and endogenous expression experiments indicated that shN4BP3 #1, #3, #4 efficiently downregulated N4BP3 expression at the protein level as suggested by immunoblot analysis (Figure 2A). In reporter assays, knockdown of N4BP3 significantly inhibited SeV-triggered activation of the IFN-β promoter and ISRE (Figure 2B). Native PAGE Western blotting showed that the reduction of endogenous N4BP3 expression could significantly reduce the formation of SeV-induced IRF3 dimerization and the phosphorylation of P65, which is a hallmark of IRF3 activation (Figure 2C). The degree of inhibition was related to how well shRNA reduced the expression of endogenous N4BP3. Consistently, knockdown of N4BP3 markedly inhibited SeV-induced transcription of IFNB1, ISG56, CXCL10 genes (Figure 2D). These data suggest that N4BP3 regulates virus-induced signaling mediated by RIG-I. From the above experimental data, #4 had the highest efficiency in reducing the expression of endogenous N4BP3, and the effect of inhibiting the RIG-I-MAVS signaling pathway was the best. Therefore, the subsequent experiment chose #4 to proceed.
FIGURE 2
Knockout of N4BP3 Inhibits RIG-I-MAVS Antiviral Signaling Pathway
To confirm the role of N4BP3 in RLR-mediated signaling, we generated two different mixed N4BP3-deficient 293T and MCF7 cells lines (KO#1 and KO#2) by CRISPR-Cas9. The knockout effect in 293T and MCF7 cells can be confirmed at DNA and protein levels (Figures 3A,B and Supplementary Figure 1C).
FIGURE 3
In reporter assays, the SeV-induced and MAVS-mediated activation of IFN-β promoter and ISRE reduced in two mix N4BP3-deficient cells compared with their control cells (Figures 3C,D). Consistently, knockout of N4BP3 significantly inhibited SeV-induced transcription of downstream genes such as IFNB1, ISG56, CXCL10 (Figure 3E). In addition, the level of virus-induced IRF3 dimerization and P65 phosphorylation in N4BP3-deficient 293T and MCF7 cells was significantly lower than that in the control group (Figure 3F). The above experiments further demonstrate that N4BP3 positively regulates the RIG-I-MAVS antiviral signal pathway.
N4BP3 Promotes the Polyubiquitination of MAVS
Ubiquitination is a key regulatory mechanism of the virus-induced innate immune response. To further investigate the mechanism by which N4BP3 positively regulates RIG-I-MAVS antiviral signal transduction, we conducted experiments on the effect of N4BP3 on the polyubiquitination of MAVS under the SeV induction. We co-transfected 293T cells with N4BP3 and MAVS, together with HA-tagged Ubi, and its mutant k48/k63, with only one lysine at positions 48 and 63, respectively, and observed that N4BP3 overexpression stimulated MAVS linked linear ubiquitination (Figure 4A). Furthermore, endogenous co-immunoprecipitation experiments indicated that N4BP3 promoted the polyubiquitination of MAVS (Figure 4C). In contrast, N4BP3 deficiency markedly decreased MAVS-mediated total polyubiquitination and k63-linked polyubiquitination (Figure 4B).
FIGURE 4
Our experiment results show that the partner of ubiquitin ligase Nedd4, Nedd4-binding protein 3 (N4BP3), interacts with MAVS and functions as a positive regulator to promote K63 polyubiquitination of MAVS in the RLR signaling pathway. These results point to the possibility that NEDD4 is a ubiquitin ligase that links N4BP3 to MAVS in RLR antiviral signaling. To test this, we examined whether the NEDD4-N4BP3 complex interacts with MAVS. The transient transfected co-immunoprecipitation experiments results showed that the NEDD4-N4BP3 complex, compared to NEDD4 alone or N4BP3 alone, showed more intense interaction with MAVS (Figure 4D). These results suggest that N4BP3 might recruit NEDD4 to MAVS in the RLR antiviral signaling. Then, we explore whether NEDD4 affects MAVS ubiquitination. The co-immunoprecipitation experiments results showed that N4BP3 or NEDD4 alone could promote K63-linked MAVS ubiquitination, and the NEDD4-N4BP3 complex could have more capability to enhance the k63 ubiquitination of MAVS (Figure 4E). All these results suggest that the possibility that N4BP3 recruits the NEDD4 ubiquitin ligase to MAVS to enhance its antiviral signaling by augmenting K63 polyubiquitination of MAVS in the RLR signaling pathway.
N4BP3 Strengthens the Interaction Between MAVS and TRAF2
After the virus infects cells, cytoplasmic RIG-I senses viral RNA promotes MAVS aggregation and recruits tumor necrosis factor receptor-associated factor (TRAF) family proteins, including TRAF2 and TRAF3 and TRAF6, activation of the downstream signaling pathway to stimulate antiviral immune responses (Hou et al., 2011; Liu et al., 2013; Hui et al., 2014). When we co-transfected 293T cells with HA-tagged MAVS and Flag-tagged TRAF2 or TRAF3, in the presence or absence of myc-tagged N4BP3, we found that N4BP3 overexpression attenuated the extent of MAVS co-precipitation with Flag-TRAF2, suggesting that N4BP3 strengthens this interaction (Figures 5A,B). The endogenous experiment was consistent with the above results (Figure 5C).
FIGURE 5
Previous research reports pointed out that the ubiquitination of TRAF2 is unintentionally important in the activation process of NF-κB, and the activation of NF-κB induces the production of downstream antiviral factors (Gudi et al., 2009; Li et al., 2009). We co-transfected myc-labeled MAVS, Flag-labeled TRAF2, HA-labeled ubiquitin plasmids and, respectively, transfected different doses of PCMV-N4BP3 into 293T cells for co-immunoprecipitation experiments. The results insinuate that N4BP3 can promote the polyubiquitination of TRAF2, a downstream complex of MAVS, and the effect of polyubiquitination was dose-dependent on N4BP3 (Figure 5D). In summary, these findings indicate that N4BP3 can promote the stability of the MAVS and TRAF2 complex and enhance the polyubiquitination of TRAF2 to achieve the positive regulation of the RIG-I-MAVS antiviral signal.
Discussion
The RIG-I-MAVS signal pathway is an indispensable antiviral innate immune signal transduction, which requires further investigation. As the central hub of the RLR signaling pathway, MAVS plays a role in linking up and down. In-depth research on MAVS will provide useful value to the RLR signaling pathway.
This study found that overexpression of N4BP3 potentiated the SeV-induced activation of ISRE and the IFNβ promoter, whereas knockdown and knockout of N4BP3 inhibited the SeV-induced transcription of downstream antiviral genes.
The N-terminal CARD domain of MAVS mediates its interaction with RLR and the important downstream targets, including TNF receptor-associated factor 2 (TRAF2). The results show that N4BP3 can indeed promote the interaction between MAVS and TRAF2. TRAF2 contains the N-terminal ring finger domain and the C-terminal highly conserved domain. Its polyubiquitination exerts biological effects and activates the NF-κB mechanism, ultimately leading to the production of IFN-β (Vallabhapurapu and Karin, 2009; Yao et al., 2014). In this study, we found that N4BP3 can enhance the polyubiquitination of TRAF2 and thus positively regulate RIG-I-MAVS signal transduction. However, how N4BP3 strengthens the interaction between MAVS and TRAF needs to be further studied.
The NEDD4 ubiquitin ligase family mainly includes NEDD4, NEDD4L, ITCH, SMURF1, SMURF2, WWP1, WWP2, NEDL1, and NEDL2 family members (Scheffner and Kumar, 2014). Among them, ITCH regulates innate antiviral immunity through the PCBP2-ITCH axis defines MAVS degradation (You et al., 2009), E3 ligase Nedd4L positively regulates antiviral immunity by catalyzing K29-linked cysteine ubiquitination of TRAF3 (Gao et al., 2021), Smurf2 targeted MAVS for K48-linked ubiquitination for its degradation (Pan et al., 2014). Our experimental results showed that overexpression of N4BP3 increases the k63-linked MAVS polyubiquitination by recruiting the NEDD4 ubiquitin ligase to MAVS for its K63-linked polyubiquitination, suggesting that N4BP3-NEDD4 complex might play an essential role to regulate RIG-I-MAVS-mediated antiviral signaling positively. Next, we need to investigate further how NEDD4 regulates the process of antiviral innate immunity by targeting MAVS.
We also found that when MAVS and N4BP3 were co-transfected, an unexpected N4BP3 degradation protein band appeared. However, this degradation band of N4BP3 disappeared when we treated the cells with crmA or the pan-caspase inhibitor BD-fmk (Supplementary Figure 1B), suggesting that MAVS-mediated N4BP3 degradation is caspase-dependent.
In summary, our research identified that N4BP3 positively regulated the antiviral innate immune signal pathway mediated by RIG-I-MAVS and provided a novel insight into the role of N4BP3 in MAVS. Further work should determine whether N4BP3 ubiquitinates MAVS through the ubiquitin link enzyme NEDD4.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.
Author contributions
L-GX designed the research. CW, TL, and NZ performed the experiments. L-GX and CW did data analysis and discussion. CW and L-GX wrote the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81971502 and 82060298).
Acknowledgments
We would like to thank Hong-Bing Shu (Medical Research Institute, Wuhan University) for his help in providing plasmids and other reagents assistance.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2021.770600/full#supplementary-material
Supplementary Figure 1(A) N4BP3 interacts with RIG-I and MAVS. 293T cells were transfected with the indicated plasmids before co-immunoprecipitation and immunoblotting analysis. (B) MAVS and N4BP3 induce fragmentation, and this is Caspase-dependent. 293T cells were transfected with the indicated plasmids for 24 h before immunoblotting analysis was performed. (C) Genomic DNA was extracted from the 293T cells and MCF7 cells of the N4BP3 KO #1 clone and KO #2 clone, and then the DNA fragments around the target area were amplified by polymerase chain reaction (PCR) and sequenced.
References
1
AkiraS.UematsuS.TakeuchiO. (2006). Pathogen recognition and innate immunity.Cell124783–801. 10.1016/j.cell.2006.02.015
2
BelgnaouiS. M.PazS.HiscottJ. (2011). Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter.Curr. Opin. Immunol.23564–572. 10.1016/j.coi.2011.08.001
3
CaiX.ChenJ.XuH.LiuS.JiangQ. X.HalfmannR.et al (2014). Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation.Cell1561207–1222. 10.1016/j.cell.2014.01.063
4
EaC. K.LiD.XiaZ. P.PinedaG.ChenZ. J. (2006). Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO.Mol. Cell.22245–257. 10.1016/j.molcel.2006.03.026
5
GaoP.MaX.YuanM.YiY.LiuG.WenM.et al (2021). E3 ligase Nedd4l promotes antiviral innate immunity by catalyzing K29-linked cysteine ubiquitination of TRAF3.Nat. Commun.12:1194. 10.1038/s41467-021-21456-1
6
GudiR.BarkingeJ.HawkinsS.PrabhakarB.KantetiP. (2009). Siva-1 promotes K-48 polyubiquitination of TRAF2 and inhibits TCR-mediated activation of NF-kappaB.J. Environ. Pathol. Toxicol. Oncol.2825–38. 10.1615/JEnvironPatholToxicolOncol.v28.i1.30
7
HeT. S.TianC.WangD. D.XuL. G. (2018). HAUS8 regulates RLR-VISA antiviral signaling positively by targeting VISA.Mole. Med. Rep.182458–2466. 10.3892/mmr.2018.9171
8
HouF.SunL.ZhengH.SkaugB.JiangQ. X.ChenZ. (2011). MAVS Forms Functional Prion-like Aggregates to Activate and Propagate Antiviral Innate Immune Response.Cell146448–461. 10.1016/j.cell.2011.06.041
9
HuiX.HeX.HuiZ.HuangL. J.HouF.YuZ.et al (2014). Structural basis for the prion-like MAVS filaments in antiviral innate immunity.eLIFE3:e01489. 10.7554/eLife.01489
10
JacobsJ. L.CoyneC. B. (2013). Mechanisms of MAVS regulation at the mitochondrial membrane.J. Mol. Biol.4255009–5019. 10.1016/j.jmb.2013.10.007
11
JanewayC. A.MedzhitovR. (2002). Innate Immune Recognition.Annu. Rev. Immunol.20197–216. 10.1146/annurev.immunol.20.083001.084359
12
KangD. C.GopalkrishnanR. V.WuQ.JankowskyE.PyleA. M.FisherP. B. (2002). mda-5: An interferon inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.PNAS99637–642. 10.1073/pnas.022637199
13
KawaiT.AkiraS. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.Immunity34637–550. 10.1016/j.immuni.2011.05.006
14
KawaiT.TakahashiK.SatoS.CobanC.AkiraS. (2005). IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.Nat. Immunol.6981–988. 10.1038/ni1243
15
KiemL. M.DietmannP.LinnemannA.SchmeisserM. J.Sj Kühl. (2017). The Nedd4 binding protein 3 is required for anterior neural development in Xenopus laevis.Dev. Biol.423466–476. 10.1016/j.ydbio.2017.01.009
16
LiS.WangL.DorfM. E. (2009). PRK phosphorylation of TRAF2 mediates IKKα/β recruitment and K63-linked polyubiquitination.Mol. Cell3330–42. 10.1016/j.molcel.2008.11.023
17
LingT.LiS. N.WengG. X.WangW.LiC.CaoL.et al (2018). TARBP2 negatively regulates IFN-beta production and innate antiviral response by targeting MAVS.Mol. Immunol.1041–10. 10.1016/j.molimm.2018.10.017
18
LiuS.ChenJ.XinC.WuJ.ChenX.WuY. T.et al (2013). MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades.eLIFE2:e00785. 10.7554/eLife.00785
19
LiuS.XinC.WuJ.QianC.ChenX.LiT.et al (2015). Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.Science347:aaa2630. 10.1126/science.aaa2630
20
MeylanE.CurranJ.HofmannK.MoradpourD.BinderM.BartenschlagerR.et al (2005). Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.Nature4371167–1172. 10.1038/nature04193
21
MurillasR.SimmsK. S.HatakeyamaS.WeissmanA. M.KuehnM. R. (2002). Identification of developmentally expressed proteins that functionally interact with nedd4 ubiquitin ligase.J. Biol. Chem.277:2897. 10.1074/jbc.M110047200
22
PanY.LiR.MengJ. L.MaoH. T.ZhangY.ZhangJ.et al (2014). Smurf2 negatively modulates RIG-I-dependent antiviral response by targeting VISA/MAVS for ubiquitination and degradation.J. Immunol.1924758–4764. 10.4049/jimmunol.1302632
23
SaitoT.HiraiR.LooY.OwenD.JohnsonC.SinhaS. (2007). Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2.PNAS104582–587. 10.1073/pnas.0606699104
24
SanjanaN. E.ShalemO.ZhangF. (2014). Improved vectors and genome-wide libraries for CRISPR screening.Nat. Methods11783–784. 10.1038/nmeth.3047
25
SatohT.KatoH.KumagaiY.YoneyamaM.SatoS.MatsushitaK.et al (2010). LGP2 is a positive regulator of RIG-I and MDA5-mediated antiviral responses.PNAS1071512–1517. 10.1073/pnas.0912986107
26
ScheffnerM.KumarS. (2014). Mammalian HECT ubiquitin-protein ligases: biological and pathophysiological aspects.Biochim. Biophys. Acta184361–74. 10.1016/j.bbamcr.2013.03.024
27
SchleeM.RothA.HornungV.HagmannC. A.WimmenauerV.BarchetW.et al (2009). Recognition of 5’ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.Immunity3125–34. 10.1016/j.immuni.2009.05.008
28
SchmidtA.SchwerdT.HammW.HellmuthJ. C.ShengC.WenzelM.et al (2009). 5’-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I.Proc. Natl. Acad. Sci. U.S.A.10612067–12072. 10.1073/pnas.0900971106
29
SethR. B.SunL.EaC. K.ChenZ. J. (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF3.Cell122669–682. 10.1016/j.cell.2005.08.012
30
ShalemO.SanjanaN. E.HartenianE.ShiX.ScottD. A.MikkelsenT. S.et al (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells.Science34384–87. 10.1126/science.1247005
31
ShiY.YuanB.QiN.ZhuW.SuJ.LiX.et al (2015). An autoinhibitory mechanism modulates MAVS activity in antiviral innate immune response.Nat. Commun.6:7811. 10.1038/ncomms8811
32
TakeuchiO.AkiraS. (2010). Pattern Recognition Receptors and Inflammation.Cell140805–820. 10.1016/j.cell.2010.01.022
33
VallabhapurapuS.KarinM. (2009). Regulation and function of NF-kappaB transcription factors in the immune system.Annu. Rev. Immunol.27693–733. 10.1146/annurev.immunol.021908.132641
34
VazquezC.HornerS. M.SullivanC. S. (2015). MAVS Coordination of Antiviral Innate Immunity.J. Virol.896974–6977. 10.1128/JVI.01918-14
35
VenkataramanT.ValdesM.ElsbyR.KakutaS.CaceresG.SaijoS.et al (2007). Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses.J. Immunol.1786444–6455. 10.4049/jimmunol.178.10.6444
36
WangZ. W.HuX.YeM.LinM.ShenX. (2020). NEDD4 E3 ligase: Functions and mechanism in human cancer.Semin. Cancer Biol.6792–101. 10.1016/j.semcancer.2020.03.006
37
WuC. J.ConzeD. B.LiT.SrinivasulaS. M.AshwellJ. D. (2006). Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation.Nat. Cell Biol.8398–406. 10.1038/ncb1384
38
XuL. G.WangY. Y.HanK. J.LiL. Y.ShuH. B. (2005). VISA is an adapter protein required for virus-triggered IFN-beta signaling.Mol. Cell.19727–740. 10.1016/j.molcel.2005.08.014
39
YaoF.LongL. Y.DengY. Z.FengY. Y.YingG. Y.BaoW. D.et al (2014). RACK1 modulates NF-kappaB activation by interfering with the interaction between TRAF2 and the IKK complex.Cell Res.24359–371. 10.1038/cr.2013.162
40
YoneyamaM.KikuchiM.NatsukawaT.ShinobuN.ImaizumiT.MiyagishiM.et al (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.Nat. Immunol.5730–737. 10.1038/ni1087
41
YouF.SunH.ZhouX.SunW.LiangS.ZhaiZ.et al (2009). PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4.Nat. Immunol.101300–1308. 10.1038/ni.1815
Summary
Keywords
N4BP3, MAVS, innate immunity, RLR antiviral signaling, TRAF2
Citation
Wang C, Ling T, Zhong N and Xu L-G (2021) N4BP3 Regulates RIG-I-Like Receptor Antiviral Signaling Positively by Targeting Mitochondrial Antiviral Signaling Protein. Front. Microbiol. 12:770600. doi: 10.3389/fmicb.2021.770600
Received
04 September 2021
Accepted
04 October 2021
Published
22 November 2021
Volume
12 - 2021
Edited by
Chunfu Zheng, University of Calgary, Canada
Reviewed by
Chenhe Su, Wistar Institute, United States; Hongjuan You, Xuzhou Medical University, China
Updates
Copyright
© 2021 Wang, Ling, Zhong and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Liang-Guo Xu, xul@jxnu.edu.cn
This article was submitted to Virology, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.